title_logo menu_logo
Pilot & Feasibility Data Search
WARNING! The DiaComp Website will be temporarily unavailable the afternoon of Saturday, May 3.
Upgrades are being made to better suit our users. Thank you for your patience!


There is strong evidence that diabetic complications are linked via dysregulation of common pathways. DiaComp promotes communication and collaboration between research communities investigating similar pathologic mechanisms in different organs by organizing an annual scientific meeting and funding new basic and translational research activities.

The interrogation of human data/samples is allowed if the applicant has IRB approval to collect/use those samples for research purposes.

NIDDK Funding Opportunity - Diabetic Complications

The NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is soliciting applications for its annual Pilot and Feasibility Program

Applications of 5 pages requesting up to $100,000 for one year are due Friday, May 16, 2014.

Current areas of interest include, but are not limited to:

  • Use of human tissue to better define the histo-pathology and -morphometry of organs affected by systemic diabetes.
  • Interrogation of human samples or resources with genetics, systems biology, histology, etc.
  • Assessment of multiple complications in model systems (C.elegans, zebrafish, drosophila, etc).
  • Testing the role of genes or loci that arise from ongoing human genetics/sequencing efforts.
  • Use of relevant model systems to accelerate gene X environment (GEI) studies.
  • Application of stem cells, including induced pluripotent stem (iPS) cells, and regenerative therapies to the repair and reversal of diabetic complications.
  • Linking and coordination of existing databases relevant to complications research.
  • Pilot studies demonstrating the feasibility of pre-consenting existing cohorts for tissue collection or linking Electronic Medical Records (EMRs) to patient samples.
  • Pilot studies to assess the role of the microbiome or virome in diabetic complications.
  • Innovative new studies to better define and understand diabetic wound healing in humans.
  • New approaches to identify genetic or epigenetic alterations associated with susceptibility to or protection from diabetic complications.
  • Pilot studies to determine if epigenetic changes in circulating cells (like pbmc’s) reflect meaningful changes in tissues or organs affected by complications.
  • Mechanistic and preclinical studies of chelation therapy (e.g. EDTA) in relevant models of complications.
  • Studies defining the role of immune cells and inflammatory pathways in initiating, exacerbating, and/or potentially resolving diabetes-induced tissue damage in complications-prone end organs.
  • Pilot projects that will directly contribute to strategies, tools, or resources for the regeneration of functional nephrons
  • Pilot studies to non-invasively image fibrosis in organs affected by diabetes.

Budget requests should be commensurate with project needs over a one year project period. While average DiaComp P&F awards are $60,000 Total Costs for one year, well justified requests for support of up to $100,000 Total Costs per year will be considered.

International institutions and organizations are eligible for support.

Applications are due May 16, 2014 for August start dates.

For instructions on how to submit a Pilot & Feasibility Funding Program Application to the DiaComp web portal please click the following link: Funding Program Application Submission Basic Training (PDF)

Applicants may request up to $60,000 (direct + indirect costs) Total Costs for one year or well justified requests for support of up to $100,000. A narrative justification should be provided only for any major equipment (cost greater than $5,000) deemed to be necessary for the proposed project. The number of awards will depend upon the number, quality, duration, and cost of the applications received.

Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at the Georgia Regents University and not directly by the NIH.

Each submitted proposal will be assigned to multiple reviewers who are either members of the DiaComp External Evaluation Committee or external scientists with expertise in the area of a proposal. Scientists from institutions submitting a proposal are in conflict and excluded from review. Final funding decisions will be made by the NIH.

December 2013 RFA for DiaComp Pilot Projects posted on NIH website, DiaComp website, MMPC websites, and notification of the postings is sent to all US academic and research institutions.
May 16, 2014 Grants Submitted to CBU (Dr. Richard McIndoe, CA 4127, Georgia Regents University, Augusta, Georgia, 30912)
August 2014 Projected start date for DiaComp Pilot Project Funding

The application is the standard PHS 398 form including face, abstract, detailed budget, biographical sketch (up to 4 pages), and research plan. The research plan should include the following sections:

  1. Specific Aims,
  2. Background and Significance,
  3. Preliminary Studies,
  4. Research Design and Methods,
  5. Literature Cited,
  6. Vertebrate Animals
  7. Sharing Plan

(Sections A-D are limited to 5 PAGES). The eligibility requirements for the Pilot and Feasibility awards are limited to full time faculty that meet the criteria described below.

NOTE: Applicants should submit one (1) paper copy to the DiaComp Coordinating and Bioinformatics Unit (CBU) at the address listed below, plus submit an electronic version of the application via the DiaComp website (PDF format only please).

Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Non-domestic (non-U.S.) Entity; Small Business; For-Profit Organization (Other than Small Business); State Government; Regional Organization; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.

Eligible Project Directors/Principal Investigators: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Young investigators are encouraged to apply.

Please note that projects devoted to the development of new techniques and tests for the metabolic characterization of mice are NOT responsive to this announcement and are better suited for the MMPC Pilot and Feasibility Grant Program (please see www.mmpc.org for more details). In brief, this program supports applications to:

  • Develop new technologies or miniaturization of existing technologies for use in mice,
  • Develop applications of existing technologies for use in mice,
  • Provide new tests to meet identifiable, outstanding needs necessary to phenotype mouse models of metabolic disease, and
  • Establish new types of mathematical models, informatics, databases or products that augment the mission of the center.

A summary of progress of funded projects is due two months following the completion of the funding period.

DiaComp awardees must follow NIH and HHS policies regarding the sharing of data and resources with the scientific community (http://grants.nih.gov/grants/sharing.htm) and agree to submit to the DiaComp web portal all data and resources resulting from the execution of the awarded application. Data and resources may include, but are not limited to:

  • histology images,
  • protocols,
  • experimental data,
  • microarray data, and
  • progress report(s).

All data and resources generated with DiaComp support will be made immediately available to “active” DiaComp awardees (see below) and publicly available on the DiaComp website: (1) at the time of first publication, or (2) two years from the date of data upload to the DiaComp website (www.diacomp.org). Under certain circumstances, investigators may request an exception to the DiaComp two year public release policy by contacting NIH Program staff and requesting a waiver. Such requests will be reviewed on a case-by-case basis and waivers will be granted only with sufficient and compelling prior justification.

DiaComp awardees are considered “active” and granted full access to the DiaComp website for the duration of their funding period plus 4 years. Outgoing awardees may request an extension from NIH Program staff beyond this “active” period.

Proprietary data and resources will be excluded from sharing consistent with NIH and HHS policies (http://grants.nih.gov/grants/sharing.htm).

Financial acknowledgment of award: Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text: 'Financial support for this work provided by the NIDDK Diabetic Complications Consortium (DiaComp, www.diacomp.org), grant DK076169'

Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Georgia Regents University
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Phone: 706-721-3542
Fax: 706-721-3688